Skip to Content

Canakinumab Dosage

Applies to the following strength(s): 180 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Familial Cold Autoinflammatory Syndrome

40 kg or less: The manufacturer product information should be consulted.
Greater than 40 kg: 150 mg subcutaneously every 8 weeks

Use: Cryopyrin-associated periodic syndromes (CAPS) including familial cold autoinflammatory syndrome (FCAS) and muckle-wells syndrome (MWS)

Usual Adult Dose for Muckle Wells Snydrome

40 kg or less: The manufacturer product information should be consulted.
Greater than 40 kg: 150 mg subcutaneously every 8 weeks

Use: Cryopyrin-associated periodic syndromes (CAPS) including familial cold autoinflammatory syndrome (FCAS) and muckle-wells syndrome (MWS)

Usual Adult Dose for Cryopyrin-Associated Periodic Syndrome

40 kg or less: The manufacturer product information should be consulted.
Greater than 40 kg: 150 mg subcutaneously every 8 weeks

Use: Cryopyrin-associated periodic syndromes (CAPS) including familial cold autoinflammatory syndrome (FCAS) and muckle-wells syndrome (MWS)

Usual Adult Dose for Familial Mediterranean Fever

40 kg or less: The manufacturer product information should be consulted.

Greater than 40 kg: 150 mg subcutaneously every 4 weeks
-If the response is inadequate: Can increase to 300 mg subcutaneously every 4 weeks

Use: Autoinflammatory periodic fever syndromes including periodic tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin d syndrome/mevalonate kinase deficiency (MKD), and familial mediterranean fever (FMF)

Usual Adult Dose for Hyperimmunoglobulin D Periodic Fever Syndrome

40 kg or less: The manufacturer product information should be consulted.

Greater than 40 kg: 150 mg subcutaneously every 4 weeks
-If the response is inadequate: Can increase to 300 mg subcutaneously every 4 weeks

Use: Autoinflammatory periodic fever syndromes including periodic tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin d syndrome/mevalonate kinase deficiency (MKD), and familial mediterranean fever (FMF)

Usual Adult Dose for Tumor Necrosis Factor Receptor Associated Periodic Fever Syndrome

40 kg or less: The manufacturer product information should be consulted.

Greater than 40 kg: 150 mg subcutaneously every 4 weeks
-If the response is inadequate: Can increase to 300 mg subcutaneously every 4 weeks

Use: Autoinflammatory periodic fever syndromes including periodic tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin d syndrome/mevalonate kinase deficiency (MKD), and familial mediterranean fever (FMF)

Usual Pediatric Dose for Familial Cold Autoinflammatory Syndrome

4 years and older:
15 to 40 kg: 2 mg/kg subcutaneously every 8 weeks
-If the response is inadequate: Can increase to 3 mg/kg subcutaneously every 8 weeks

Greater than 40 kg: 150 mg subcutaneously every 8 weeks

Use: For the treatment of CAPS including FCAS and MWS

Usual Pediatric Dose for Muckle Wells Snydrome

4 years and older:
15 to 40 kg: 2 mg/kg subcutaneously every 8 weeks
-If the response is inadequate: Can increase to 3 mg/kg subcutaneously every 8 weeks

Greater than 40 kg: 150 mg subcutaneously every 8 weeks

Use: For the treatment of CAPS including FCAS and MWS

Usual Pediatric Dose for Cryopyrin-Associated Periodic Syndrome

4 years and older:
15 to 40 kg: 2 mg/kg subcutaneously every 8 weeks
-If the response is inadequate: Can increase to 3 mg/kg subcutaneously every 8 weeks

Greater than 40 kg: 150 mg subcutaneously every 8 weeks

Use: For the treatment of CAPS including FCAS and MWS

Usual Pediatric Dose for Familial Mediterranean Fever

2 years and older:
40 kg or less: 2 mg/kg subcutaneously every 4 weeks
-If the response is inadequate: Can Increase to 4 mg/kg subcutaneously every 4 weeks

Greater than 40 kg: 150 mg subcutaneously every 4 weeks
-If the response is inadequate: Can increase to 300 mg subcutaneously every 4 weeks

Use: For the treatment of autoinflammatory periodic fever syndromes including TRAPS, HIDS/MKD, and FMF

Usual Pediatric Dose for Hyperimmunoglobulin D Periodic Fever Syndrome

2 years and older:
40 kg or less: 2 mg/kg subcutaneously every 4 weeks
-If the response is inadequate: Can Increase to 4 mg/kg subcutaneously every 4 weeks

Greater than 40 kg: 150 mg subcutaneously every 4 weeks
-If the response is inadequate: Can increase to 300 mg subcutaneously every 4 weeks

Use: For the treatment of autoinflammatory periodic fever syndromes including TRAPS, HIDS/MKD, and FMF

Usual Pediatric Dose for Tumor Necrosis Factor Receptor Associated Periodic Fever Syndrome

2 years and older:
40 kg or less: 2 mg/kg subcutaneously every 4 weeks
-If the response is inadequate: Can Increase to 4 mg/kg subcutaneously every 4 weeks

Greater than 40 kg: 150 mg subcutaneously every 4 weeks
-If the response is inadequate: Can increase to 300 mg subcutaneously every 4 weeks

Use: For the treatment of autoinflammatory periodic fever syndromes including TRAPS, HIDS/MKD, and FMF

Usual Pediatric Dose for Juvenile Idiopathic Arthritis

2 years and older weighing at least 7.5 kg: 4 mg/kg subcutaneously every 4 weeks
Maximum dose: 300 mg

Comments:
-Approved dosing is only for 7.5 kg or more.

Use: For the treatment of active systemic juvenile idiopathic arthritis (SJIA)

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CAPS: Safety and efficacy have not been established in patients younger than 4 years.
TRAPS, HIDS/MKD, FMF: Safety and efficacy have not been established in patients younger than 2 years.
SJIA: Safety and efficacy have not been established in patients younger than 2 years or weighing less than 7.5 kg.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Avoid injection into scar tissue.
-Vials are intended for single use in 1 patient; discard any unused portion.

Storage requirements:
-The manufacturer product information should be consulted.

Reconstitution/preparation techniques:
-The manufacturer product information should be consulted.

IV compatibility:
-The manufacturer product information should be consulted.

Hide